Bempedoic Acid
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
Bempedoic acid: ATP-citrate lyase inhibitor → hyperthyroidism
One-Sentence Summary
Bempedoic acid is an oral lipid-lowering drug that inhibits ATP-citrate lyase (ACL) and is marketed in Canada as NILEMDO. The TxGNN model predicts it may be relevant to hyperthyroidism, but this is a model prediction only, with 0 clinical trials and 0 publications currently supporting it.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | hyperthyroidism |
| TxGNN Prediction Score | 0.9961 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 1 of 1) |
| Number of DINs | 1 (marketed: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data are not available in the data compiled for this report. From general pharmacology, bempedoic acid inhibits ACL, an enzyme upstream of HMG-CoA reductase in hepatic cholesterol synthesis, and thereby lowers LDL cholesterol.
No clear mechanistic link to hyperthyroidism has been identified. Thyroid hormone status influences lipid metabolism, but that does not imply that an ACL inhibitor would treat excess thyroid hormone production. The high score is a model-based prediction only and is not backed by any trial or publication. The prediction should be treated as a hypothesis, not as evidence of benefit.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02562782 | NILEMDO | Not recorded | Not recorded |
Safety Considerations
- Drug Interactions: 23 interactions were recorded in total; the 20 listed in the compiled data include:
- Major: systemic corticosteroids (hydrocortisone, prednisone, prednisolone, methylprednisolone, dexamethasone, betamethasone, triamcinolone, budesonide, deflazacort, fludrocortisone), levofloxacin, and simvastatin.
- Moderate: rosuvastatin, empagliflozin, glyburide, repaglinide, rifaximin, selexipag, fexofenadine, and revefenacin.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a model score. No clinical trials or publications address hyperthyroidism, and no plausible mechanistic link exists, so the evidence level is L5.
To proceed, the following is needed:
- Mechanistic or preclinical evidence linking ACL inhibition to thyroid hormone excess
- Any clinical or observational data on bempedoic acid in thyroid disease
- Package insert warnings and contraindications from Health Canada
- Detailed mechanism-of-action data and a review of the interaction profile
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.